Milestone Pharmaceuticals Inc.MIST
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · Canada · milestonepharma.com
Montreal-based biopharmaceutical company developing cardiovascular medicines. Its lead product CARDAMYST (etripamil) nasal spray is FDA-approved for the acute conversion of paroxysmal supraventricular tachycardia.
Key ratios
FCF / Sales
-2631.1%TTM
2025
-3191.6%2023
-4653.5%
ROA
-42.8%TTM
2025
-41.1%2024
-34.9%2023
-51.0%
ROE
-35522.6%TTM
2025
-229.7%2024
-277.6%2023
-143.6%
Revenue growth
-100.0%TTM
2023
-80.0%
Recent news
Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States
Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients' Daily Lives and Quality of Life Between Episodes
Track MIST in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer